Pharmaceutical Raw Materials Lisinopril Powder

CAS:76547-98-3

MF:C21H31N3O5

MW:405.49

EINECS:278-488-1

Specification: 99% min Lisinopril Powder

Sample:Lisinopril Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White to Off-White

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Lisinopril Powder Usage and Synthesis.

Lenopril is a third-generation angiotensin-converting enzyme inhibitor, a lysine derivative of enalapril, which has been marketed in the United States since 1987 for the treatment of hypertension, and is the first-line treatment for anti-hypertensive diseases.

Pharmacological characteristics are similar to Enalapril, with strong angiotensin-converting enzyme inhibition, fast onset of action, long duration of action, and can be taken once a day.

The inhibitory effect on ACE is 6-8 times of captopril and 1-3 times of benazepril.

It can make the total peripheral resistance and blood pressure drop significantly, but not accompanied by reflex tachycardia. Lenopril can reduce pulmonary wedge pressure, increase cardiac output, increase left ventricular ejection fraction and improve cardiac function in patients with heart failure.

It can increase renal blood flow, reduce renal vascular resistance and increase glomerular filtration rate.

It can be used alone or in combination with other drugs to treat various degrees of hypertension and renal hypertension that are not treated by other anti-hypertensive drugs, and can also be used alone or in combination with digitalis and diuretics to treat congestive heart failure.

It can also be used as adjunctive therapy for those who are haemodynamically stable after acute myocardial infarction.

Uses and functions of Lisinopril.

It is used in the treatment of essential hypertension and renal vascular hypertension, either alone or in combination with other classes of antihypertensives such as diuretics.

In patients with congestive heart failure, this product may be added when digitalis or diuretics are not effective.

Pharmacological Effect of Lisinopril.

1. Lenopril is a synthetic peptide derivative that is an orally administered, long-acting inhibitor of the enzyme angiotensin-converting enzyme.

Lenopril is a synthetic peptide derivative which is an orally administered long-acting inhibitor of the enzyme angiotensin converting enzyme. It reduces the concentration of angiotensin (a strong vasoconstrictor) and aldosterone, which leads to the dilation of peripheral vasculature and the reduction of vascular roaring force to lower blood pressure.

Research data show that the therapeutic effect of long-term use of this product does not diminish, and immediate discontinuation of the drug does not cause a rebound in blood pressure.

In patients with congestive heart failure, Lenopril reduces cardiac preload and afterload by dilating arteries and veins, increasing cardiac output without reflex tachycardia.

This product seldom produces low blood god and excessive blood uric acid caused by hawkazines.

2. Literature reports: the LD50 value of orally administered lynopril in mice is greater than 9100mg/kp, the LD50 value of orally administered lynopril in mice is greater than F8500mg/kg, and the LD50 value of orally administered lynopril in dogs is greater than 6000mg/kg.

Drug interactions of  Bulk Lisinopril Powder.

1. Combined use with diuretics: The antihypertensive effect is usually enhanced by the addition of diuretics in patients treated with this product.

In patients already treated with diuretics and especially those recently treated with diuretics, excessive lowering of blood pressure may occur when this product is added.

The likelihood of symptomatic hypotension can be greatly reduced by discontinuing diuretics prior to initiating treatment with this product. Start with a small dose of this product and adjust the dose gradually.

2. The antihypertensive effect is enhanced when used with other antihypertensive drugs. Among them, it has a greater additive effect with drugs causing renin release or affecting sympathetic activity, and a less than additive effect with β-blockers.

3, and retention of potassium diuretic drugs such as spironolactone, ampicillin, amiloride with the use of blood potassium may cause excessive.

4, non-steroidal anti-inflammatory painkillers, especially indomethacin (indomethacin) can inhibit prostaglandin synthesis and cause water and sodium retention, when used with this product can make the antihypertensive effect of this product weakened.